Cargando…
Bivalirudin in percutaneous coronary intervention
Bivalirudin is a member of the direct thrombin inhibitor group of anticoagulants. It has been evaluated as an alternative to unfractionated and low-molecular-weight heparins in the settings of percutaneous coronary intervention (PCI) and acute coronary syndrome (ACS). Results of clinical trials to d...
Autores principales: | Lehman, Sam J, Chew, Derek P |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2006
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1994003/ https://www.ncbi.nlm.nih.gov/pubmed/17323589 |
Ejemplares similares
-
Percutaneous coronary intervention in patients with acute coronary syndrome: focus on bivalirudin
por: Ramana, Ravi K, et al.
Publicado: (2008) -
The Rise and Fall of Anticoagulation with Bivalirudin During Percutaneous Coronary Interventions: A Review Article
por: Andreou, Constantinos, et al.
Publicado: (2017) -
The effect of bivalirudin and closure device on bleeding outcomes after percutaneous coronary interventions
por: Dobies, David R, et al.
Publicado: (2014) -
Relative efficacy of bivalirudin versus heparin monotherapy in patients with ST-segment elevation myocardial infarction treated with primary percutaneous coronary intervention: a network meta-analysis
por: Kinnaird, Tim, et al.
Publicado: (2013) -
Bivalirudin Versus Heparin During Percutaneous Coronary Intervention in Patients With Acute Myocardial Infarction
por: Patel, Hiten, et al.
Publicado: (2019)